Rexulti, Advertising Profile, See Their Ad Spend!
Descrição
REXULTI (Depression) TV Commercials
FDA approves Rexulti for agitation tied to Alzheimer's dementia, Daily therapy is first to be approved for this use in US
Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole - Kikuchi - 2021 - Neuropsychopharmacology Reports - Wiley Online Library
Solved Order: Rexulti 1 mg p.o. daily for 4 days for a
Pre Mid-Terms: Political Ads Capture Attention
Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Alzheimer's Dementia
Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of Supplemental New Drug Application (sNDA) for REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease
Rexulti Post-Launch HCP Website - Once Daily Pharma
PM360 2021 Trailblazer Awards Co-Promote or Partnership Initiative Gold Winner Otsuka, Lundbeck, and The Bloc
REXULTI® (brexpiprazole), MDD
Social Ad Spend Surpasses Television: New Research : Social Media Examiner
Digital Ads Benchmark Report By Tinuiti, Q2 2023
REXULTI TV Spot, 'Hard Enough'
de
por adulto (o preço varia de acordo com o tamanho do grupo)
